Attralus, Inc. has raised a $116m series B financing that it says will bring the first of its pan-amyloid removal (PAR) drug candidates into the clinic and advance development of a diagnostic for detecting systemic amyloidosis. The South San Francisco, CA-based firm announced the round on 8 September, less than a year after its introduction with a series A financing.
Attralus drew some attention this past May when it hired former Purdue Pharma L.P. CEO Mark Timney as its new top executive. Timney tried unsuccessfully to diversify Purdue’s focus beyond opioid analgesic medicine before the company filed for bankruptcy over a deluge of lawsuits related to its sale and marketing of opioid therapeutics
